非布司他治疗痛风及高尿酸血症的临床疗效及其安全性
摘要
目的探讨非布司他治疗痛风及高尿酸血症的临床疗效及其安全性。方法选取孝昌县第一人民医院2015年5月—2018年1月收治的痛风及高尿酸血症患者200例,按照随机数字表法分为观察组与对照组,各100例。对照组患者予以别嘌醇治疗,观察组患者予以非布司他治疗。比较两组患者治疗前后血尿酸水平,并观察两组患者不良反应情况。结果治疗前两组患者血尿酸水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血尿酸水平低于对照组(P<0.05)。观察组患者不良反应发生率低于对照组(P<0.05)。结论非布司他治疗痛风及高尿酸血症可有效降低患者血尿酸水平,且安全性较高。
引文
[1]万志红.非布司他治疗痛风及高尿酸血症的疗效及不良反应观察[J].中国实用医药,2016,11(1):112-113.
[2]陈松,黄健,杨静,等.非布司他治疗慢性肾脏病伴高尿酸血症的临床研究[J].实用医学杂志,2016,32(3):472-474.
[3]任庆杰,张旭环,陈铁霁,等.非布司他治疗痛风伴高尿酸血症、肾功能不全患者的疗效观察[J].现代实用医学,2016,28(9):1174-1176.
[4]鄢海波,马宁,崔春丽,等.非布司他治疗痛风性关节炎的疗效及其安全性评价[J].吉林大学学报(医学版),2017,43(1):135-140,216-217.
[5]PETERMANN J,BONNEFOND R,MERMOUD I,et al.Evaluation of three adjuvants with respect to both adverse effects and the efficacy of antibody production to the Bm86 protein[J].Experimental and Applied Acarology,2017,72(3).
[6]黄金沐,池慧琼,林少凯.比较非布司他片与别嘌呤醇片治疗高尿酸血症伴痛风的临床研究[J].中国临床药理学杂志,2017,33(20):2009-2012.
[7]杨婷,路敏,周颖,等.非布司他和别嘌醇治疗痛风有效性和安全性的Meta分析[J].中国临床药理学杂志,2015,31(2):122-126.
[8]蒋兰兰,金星,沈赟,等.非布司他治疗痛风伴高尿酸血症患者的有效性及安全性[J].实用医学杂志,2014,30(17):2827-2830.
[9]YU K H,LAI J H,PN H,et al.Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout:a randomized,openlabel,multicentre,allopurinol-controlled study[J].Scandinavian Journal of Rheumatology,2016,45(4):304-311.
[10]HOOFT J M,BUREAU D P.Evaluation of the efficacy of a commercial feed additive against the adverse effects of feedborne deoxynivalenol(DON)on the performance of rainbow trout(Oncorhynchus mykiss)[J].Aquaculture,2017,473:237-245.
[11]BARDIN T,CHALES G,PASCART T,et al.Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol.A retrospective,hospital-based study of 101patients with consecutive allopurinol and febuxostat treatment[J].Joint Bone Spine,2015,83(3):314-317.
[12]CHEN J H,LAN J L,CHENG C F,et al.Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout:a case-matched cohort study[J].Plos One,2015,10(12):e0145193.
[13]蒋立英.非布司他治疗痛风并高尿酸血症患者的疗效及不良反应分析[J].临床医药文献电子杂志,2017,4(58):11373-11374.
[2]陈松,黄健,杨静,等.非布司他治疗慢性肾脏病伴高尿酸血症的临床研究[J].实用医学杂志,2016,32(3):472-474.
[3]任庆杰,张旭环,陈铁霁,等.非布司他治疗痛风伴高尿酸血症、肾功能不全患者的疗效观察[J].现代实用医学,2016,28(9):1174-1176.
[4]鄢海波,马宁,崔春丽,等.非布司他治疗痛风性关节炎的疗效及其安全性评价[J].吉林大学学报(医学版),2017,43(1):135-140,216-217.
[5]PETERMANN J,BONNEFOND R,MERMOUD I,et al.Evaluation of three adjuvants with respect to both adverse effects and the efficacy of antibody production to the Bm86 protein[J].Experimental and Applied Acarology,2017,72(3).
[6]黄金沐,池慧琼,林少凯.比较非布司他片与别嘌呤醇片治疗高尿酸血症伴痛风的临床研究[J].中国临床药理学杂志,2017,33(20):2009-2012.
[7]杨婷,路敏,周颖,等.非布司他和别嘌醇治疗痛风有效性和安全性的Meta分析[J].中国临床药理学杂志,2015,31(2):122-126.
[8]蒋兰兰,金星,沈赟,等.非布司他治疗痛风伴高尿酸血症患者的有效性及安全性[J].实用医学杂志,2014,30(17):2827-2830.
[9]YU K H,LAI J H,PN H,et al.Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout:a randomized,openlabel,multicentre,allopurinol-controlled study[J].Scandinavian Journal of Rheumatology,2016,45(4):304-311.
[10]HOOFT J M,BUREAU D P.Evaluation of the efficacy of a commercial feed additive against the adverse effects of feedborne deoxynivalenol(DON)on the performance of rainbow trout(Oncorhynchus mykiss)[J].Aquaculture,2017,473:237-245.
[11]BARDIN T,CHALES G,PASCART T,et al.Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol.A retrospective,hospital-based study of 101patients with consecutive allopurinol and febuxostat treatment[J].Joint Bone Spine,2015,83(3):314-317.
[12]CHEN J H,LAN J L,CHENG C F,et al.Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout:a case-matched cohort study[J].Plos One,2015,10(12):e0145193.
[13]蒋立英.非布司他治疗痛风并高尿酸血症患者的疗效及不良反应分析[J].临床医药文献电子杂志,2017,4(58):11373-11374.